Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”

Agnes Kant and Florence Hunsel ()
Additional contact information
Agnes Kant: Netherlands Pharmacovigilance Centre Lareb
Florence Hunsel: Netherlands Pharmacovigilance Centre Lareb

Drug Safety, 2022, vol. 45, issue 8, No 10, 925-926

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01207-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:8:d:10.1007_s40264-022-01207-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01207-x

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().